GSK Plc (GSK)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about GSK Plc (GSK)
Company Performance

Current Price

as of Oct 16, 2024

$19.45

P/E Ratio

15.08

Market Cap

$79.19B

Description

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Metrics

Overview

  • HQLondon, GL
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerGSK
  • Price$19.453381-0.44%

Trading Information

  • Market Cap$79.19B
  • Float92.11%
  • Average Daily Volume (1m)6,450,719
  • Average Daily Volume (3m)5,000,871
  • EPS$0.99

Company

  • Revenue$31.45B
  • Rev Growth (1yr)9.84%
  • Net Income$1.17B
  • Gross Margin73.60%
  • EBITDA Margin33.28%
  • EBITDA$2.62B
  • EV$76.40B
  • EV/Revenue2.43
  • P/E15.08
  • P/S1.96
  • P/B4.25
Documents
Factset Street Account
StreetAccount Metrics Recap - GSK Plc Q3 Earnings (1457.4000p, 0) (2023-11-01T07:11:48Z)
StreetAccount Earnings Call Q&A Summary: GSK Plc Q3 (1425.8000p, -31.6) (2023-11-01T14:50:30Z)
GSK's Arexvy phase III trial show primary endpoints met with non-inferior immune responses observed in adults aged 50-59 compared to adults aged 60 and older (1470.0000p, 0) (2023-10-25T08:37:16Z)
GSK Plc reports Q3 adj EPS 50.4p vs consensus 46.0p; raises FY23 guidance (1457.4000p, 0) (2023-11-01T07:05:44Z)
GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials (1408.0000p, 0) (2023-11-21T08:12:18Z)
GSK announces Health Canada approves Jemperli (dostarlimab for injection) plus carboplatin and paclitaxel as a treatment option for primary advanced or recurrent dMMR/MSI-H endometrial cancer (1385.4000p, -7.4) (2023-11-16T13:02:24Z)
GSK announces DREAMM-7 met its primary endpoint of progression-free survival (PFS) (1422.6000p, 0) (2023-11-27T07:03:38Z)
GSK announced positive headline results from a planned analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli plus standard-of-care chemotherapy (carboplatin and paclitaxel) (1433.2000p, 0) (2023-10-30T07:06:14Z)
FDA grants orphan drug designation to BVL-GSK098 for tuberculosis (1395.8000p, +0.2) (2023-11-06T15:06:21Z)
EU's CHMP gives positive opinion recommending GSK's momelotinib for myelofibrosis patients with anaemia (1398.4000p, 0) (2023-11-13T07:04:22Z)
EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Omjjara (1407.0000p, -8.4) (2023-11-10T12:29:58Z)
EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Jemperli (1510.4000p, -9.4) (2023-10-13T11:51:09Z)
Factset
Factset Business Description
Wikipedia
GSK_plc